How do I install the Icsm Testosterone Monitoring Schedule skill?

Run npx skillmds@latest add dromlakhani/icsm-testosterone-monitoring-schedule in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Icsm Testosterone Monitoring Schedule safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Icsm Testosterone Monitoring Schedule?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Icsm Testosterone Monitoring Schedule free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Icsm Testosterone Monitoring Schedule?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Icsm Testosterone Monitoring Schedule by dromlakhani

Name: Icsm Testosterone Monitoring Schedule
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Icsm Testosterone Monitoring Schedule

This skill outlines the monitoring schedule for testosterone therapy, detailing baseline, 3‑month, 6‑month, and yearly assessments of symptoms, adverse events, total testosterone, hematocrit, PSA, and DRE. Use it when a patient is receiving testosterone and the clinician asks what labs and checks are needed today or when the next monitoring visit should occur.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Follow testosterone therapy monitoring schedule

STEP 1 — Gather Information

Confirm the patient is on testosterone therapy, note the date of initiation, and record the date of the last monitoring visit; collect any new symptoms or adverse events reported since the last check.

STEP 2 — Rule In / Rule Out

If the time since the last visit matches a scheduled interval (baseline, 3 months, 6 months, or >12 months), proceed to classify the required assessments; otherwise, inform the patient that no monitoring is due today and schedule the next visit based on the interval.

STEP 3 — Classify or Stratify

Determine which assessments are due for this visit: symptoms evaluation and adverse events are always checked; total testosterone and hematocrit are due at baseline, 3 months, 6 months, and yearly; PSA is due at baseline, 3 months, 6 months, and yearly; DRE is due at baseline and 6 months (per Table 4).

STEP 4 — Decide

Order the indicated laboratory tests (total testosterone, hematocrit, PSA), perform symptom and adverse event review, and conduct DRE if the visit aligns with the 6‑month or baseline point; document results and adjust testosterone dose if hematocrit exceeds 54% or if symptomatic adverse events arise.

Clinical Guardrails / Mimics / Pitfalls

Do not omit hematocrit monitoring due to the risk of testosterone‑induced polycythemia; avoid delaying PSA or DRE when indicated, as prostate assessment is required before and during therapy; never rely solely on symptom changes without corroborating labs; ensure testosterone is drawn fasting between 07:00–11:00 h for accurate interpretation.

Concrete Clinical Example

A 52‑year‑old man started testosterone enanthate 100 mg weekly 4 months ago. He reports no new symptoms. According to the schedule, a 3‑month visit is overdue; you order total testosterone, hematocrit, PSA, review symptoms and adverse events, and note that DRE is not required until the 6‑month mark. His hematocrit is 52 %, testosterone is 520 ng/dL, PSA 1.1 ng/mL; you continue the current dose and schedule the next visit in 3 months (for the 6‑month assessment).

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036

---name: icsm-testosterone-monitoring-scheduledescription: This skill outlines the monitoring schedule for testosterone therapy, detailing baseline, 3‑month, 6‑month, and yearly assessments of symptoms, adverse events, total testosterone, hematocrit, PSA, and DRE. Use it when a patient is receiving testosterone and the clinician asks what labs and checks are needed today or when the next monitoring visit should occur.---# Follow testosterone therapy monitoring schedule## STEP 1 — Gather InformationConfirm the patient is on testosterone therapy, note the date of initiation, and record the date of the last monitoring visit; collect any new symptoms or adverse events reported since the last check.## STEP 2 — Rule In / Rule OutIf the time since the last visit matches a scheduled interval (baseline, 3 months, 6 months, or >12 months), proceed to classify the required assessments; otherwise, inform the patient that no monitoring is due today and schedule the next visit based on the interval.## STEP 3 — Classify or StratifyDetermine which assessments are due for this visit: symptoms evaluation and adverse events are always checked; total testosterone and hematocrit are due at baseline, 3 months, 6 months, and yearly; PSA is due at baseline, 3 months, 6 months, and yearly; DRE is due at baseline and 6 months (per Table 4).## STEP 4 — DecideOrder the indicated laboratory tests (total testosterone, hematocrit, PSA), perform symptom and adverse event review, and conduct DRE if the visit aligns with the 6‑month or baseline point; document results and adjust testosterone dose if hematocrit exceeds 54% or if symptomatic adverse events arise.## Clinical Guardrails / Mimics / PitfallsDo not omit hematocrit monitoring due to the risk of testosterone‑induced polycythemia; avoid delaying PSA or DRE when indicated, as prostate assessment is required before and during therapy; never rely solely on symptom changes without corroborating labs; ensure testosterone is drawn fasting between 07:00–11:00 h for accurate interpretation.## Concrete Clinical ExampleA 52‑year‑old man started testosterone enanthate 100 mg weekly 4 months ago. He reports no new symptoms. According to the schedule, a 3‑month visit is overdue; you order total testosterone, hematocrit, PSA, review symptoms and adverse events, and note that DRE is not required until the 6‑month mark. His hematocrit is 52 %, testosterone is 520 ng/dL, PSA 1.1 ng/mL; you continue the current dose and schedule the next visit in 3 months (for the 6‑month assessment).**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036

Frequently asked questions